Ridinilazole

Ridinilazole
Systematic (IUPAC) name
2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-1H-benzimidazole
Identifiers
CAS Number 308362-25-6
PubChem CID 16659285
ChemSpider 17592423
Synonyms SMT19969
Chemical data
Formula C24H16N6
Molar mass 388.42 g/mol

Ridinilazole (SMT19969) is a non-absorbable[1] small molecule antibiotic for oral administration to treat Clostridium difficile infection (CDI).[2]

As of October 2015 its mechanism of action "remains to be fully determined".[1]

In preclinical studies, ridinilazole showed a potent bactericidal effect against all strains of C. difficile tested.[2]

In a Phase 2 proof of concept trial in CDI patients (‘CoDIFy’), ridinilazole showed statistical superiority in sustained clinical response (‘SCR’) rates compared to the standard of care, vancomycin. In this trial, SCR was defined as clinical cure at end of treatment and no recurrence of CDI within 30 days of the end of therapy.[2] SCR rates were 66.7% for ridinilazole compared to 42.4% for vancomycin.[3][4]

Ridinilazole has received Qualified Infectious Disease Product (‘QIDP’) designation and has been granted Fast Track status by the US FDA.[2]

References

  1. 1 2 Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. 2015
  2. 1 2 3 4 Summit Therapeutics Announces Publication of Preclinical Data Showing Ridinilazole Outperformed Standard of Care in Reducing C. Difficile Toxins That Drive Disease Symptoms. Feb 2016
  3. ↑ Summit Therapeutics Announces Novel Antibiotic Ridinilazole (SMT19969) Achieves Statistical Superiority Over Vancomycin in CoDIFy Phase 2 Clinical Trial for C. difficile Infection. Nov 2015
  4. ↑ New Drugs Online Report for ridinilazole
This article is issued from Wikipedia - version of the Friday, April 15, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.